Jonas Salk laboratory. He later joined the National Foundation for Infantile Paralysis's polio project established by President Franklin D. Roosevelt. Extensive publicity and fear of polio led to much increased funding, $67 million by 1955, but research continued on dangerous live vaccines. Salk decided to use the safer 'killed' virus, instead of weakened forms of strains of polio viruses like the ones used contemporarily by Albert Sabin, who was developing an oral vaccine. After successful tests on laboratory animals, on July 2, 1952, assisted by the staff at the D.T. Watson Home for Crippled Children, Salk injected 43 children with his killed-virus
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS